Integrated Biopharma, Inc.
INBP
$0.30
$0.00-0.27%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -11.10% | -10.48% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -11.10% | -10.48% | |||
| Cost of Revenue | -3.59% | -8.15% | |||
| Gross Profit | -97.15% | -30.63% | |||
| SG&A Expenses | 10.16% | -2.73% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.65% | -7.80% | |||
| Operating Income | -660.74% | -72.33% | |||
| Income Before Tax | -545.92% | -67.06% | |||
| Income Tax Expenses | -253.42% | -90.56% | |||
| Earnings from Continuing Operations | -719.51% | 169.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -719.51% | 169.10% | |||
| EBIT | -660.74% | -72.33% | |||
| EBITDA | -448.33% | -63.64% | |||
| EPS Basic | -712.50% | 168.97% | |||
| Normalized Basic EPS | -551.28% | -68.29% | |||
| EPS Diluted | -869.23% | 167.24% | |||
| Normalized Diluted EPS | -551.28% | -68.29% | |||
| Average Basic Shares Outstanding | 0.00% | 1.47% | |||
| Average Diluted Shares Outstanding | -1.15% | 2.65% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||